Axxam SpA and and the Swiss startup leadXpro AG collaborate for the discovery of novel small molecule lead compounds for a newly discovered receptor involved in inflammatory processes. The project is co-funded by the State Secretariat for Education, Research and Innovation and the European Union.
In the collaboration, Axxam and leadXpro will combine their expertise in assay development, high throughput screening, membrane protein generation, structure determination and application of biophysical methods to investigate the interaction of small molecule ligands with challenging membrane protein drug targets to facilitate the discovery and optimization of novel lead molecules.
Michael Hennig (CEO, leadXpro) said: “We’re excited to complement our capabilities on structure-based drug discovery with the strength of Axxam in assay development and screening. The funding support from Eurostars significantly facilitates this collaboration between the companies.”
Chiara Liberati (Director, Discovery Research, Axxam) said: “This recently discovered GPCR needs joint efforts in order to identify bioactive small molecules able to modulate it. The complementary skill sets of both companies in the GPCR field are necessary to fully explore the therapeutic potential of this fascinating target.”
(Press release)
0Comments
More news about
Please login or sign up to comment.
Commenting guidelines